Longitudinal trends in prostate cancer incidence, mortality, and survival of patients from two Shanghai city districts: A retrospective population-based cohort study, 2000-2009

BMC Public Health

Volumn 14, Issue 1, 2014, Pages

  Hu, Yi ^a   Zhao, Qi ^a   Rao, Jianyu ^b   Deng, Haiju ^c   Yuan, Hong ^c   Xu, Biao ^a  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Shanghai Center for Disease Control and Prevention   (China)

Author keywords

China; Incidence; Mortality; Prostate cancer; Survival

Indexed keywords

ADULT; AGED; CHINA; CITY; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; SURVIVAL RATE; URBAN POPULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHINA; CITIES; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RESEARCH DESIGN; RETROSPECTIVE STUDIES; SURVIVAL RATE; URBAN POPULATION;

EID: 84899944634     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-14-356     Document Type: Article

References (23)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 10 [Internet] Lyon, France: International Agency for Research on Cancer 2010 Available from: http://globocan.iarc.fr [accessed 23/02/2014]
2. Rising incidence of prostate cancer in Shanghai, China. Hsing AW, Devesa SS, Jin F, Gao YT, Cancer Epidemiol Biomarkers Prev 1998 7 1 83 84 9456247
3. Secular trends in body mass index and the prevalence of overweight and obesity among children and adolescents in Shandong, China, from 1985 to 2010. Ying-Xiu Z, Shu-Rong W, J Public Health (Oxf) 2012 34 1 131 137 10.1093/pubmed/fdr053 21742740
4. American Urological Association releases guidelines for the management of localized prostate cancer. Am Fam Physician 1996 53 8 2751 2752 8644580
5. Tumour grade, treatment, and relative survival in a population-based cohort of men with potentially curable prostate cancer. Ladjevardi S, Sandblom G, Berglund A, Varenhorst E, Eur Urol 2010 57 4 631 638 10.1016/j.eururo.2009. 03.007 19299069
6. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M, Cancer Epidemiol 2013 37 3 219 225 10.1016/j.canep.2013.02.002 23485480
7. Population-based evidence of increased survival in human papillomavirus-related head and neck cancer. Nygard M, Aagnes B, Bray F, Moller B, Mork J, Eur J Cancer 2012 48 9 1341 1346 10.1016/j.ejca.2012.03.014 22516210
8. Evaluation of prostate cancer characteristics in four populations worldwide. Zeigler-Johnson CM, Rennert H, Mittal RD, Jalloh M, Sachdeva R, Malkowicz SB, Mandhani A, Mittal B, Gueye SM, Rebbeck TR, Can J Urol 2008 15 3 4056 4064 18570709
9. Familial risk and familial survival in prostate cancer. Hemminki K, World J Urol 2012 30 2 143 148 10.1007/s00345-011-0801-1 22116601
10. Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. Brandt A, Sundquist J, Hemminki K, Ann Oncol 2012 23 1 251 256 10.1093/annonc/mdr056 21467126
11. A high-fat diet enhances proliferation of prostate cancer cells and activates MCP-1/CCR2 signaling. Huang M, Narita S, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Tsuchiya N, Habuchi T, Prostate 2012 72 16 1779 1788 10.1002/pros.22531 22514016
12. Diet and prostate cancer prevention. Marshall JR, World J Urol 2012 30 2 157 165 10.1007/s00345-011-0810-0 22249340
13. The relationship between obesity and prostate cancer: from genetics to disease treatment and prevention. Lughezzani G, BMC Med 2012 10 109 10.1186/1741-7015-10-109 23009325
14. Obesity, body composition, and prostate cancer. Fowke JH, Motley SS, Concepcion RS, Penson DF, Barocas DA, BMC Cancer 2012 12 23 10.1186/1471-2407- 12-23 22257467
15. Epidemiology of general obesity, abdominal obesity and related risk factors in urban adults from 33 communities of Northeast China: the CHPSNE study. Wang H, Wang J, Liu MM, Wang D, Liu YQ, Zhao Y, Huang MM, Liu Y, Sun J, Dong GH, BMC Public Health 2012 12 967 10.1186/1471-2458-12-967 23146089
16. Estimation of cancer incidence and mortality attributable to overweight, obesity, and physical inactivity in China. Wang D, Zheng W, Wang SM, Wang JB, Wei WQ, Liang H, Qiao YL, Boffetta P, Nutr Cancer 2012 64 1 48 56 10.1080/01635581.2012.630166 22136606
17. The emerging epidemic of obesity, diabetes, and the metabolic syndrome in China. Shen J, Goyal A, Sperling L, Cardiol Res Pract 2012 2012 178675 21961074
18. Obesity and overweight prevalence and its association with undiagnosed hypertension in Shanghai population, China: a cross-sectional population-based survey. Li X, Xu J, Yao H, Guo Y, Chen M, Lu W, Front Med 2012 6 3 322 328 10.1007/s11684-012-0204-8 22843305
19. Prostate-cancer mortality at 11 years of follow-up. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Paez A, Maattanen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A, N Engl J Med 2012 366 11 981 990 10.1056/NEJMoa1113135 22417251
20. Prostate cancer incidence, mortality, and survival trends in the United States: 1981-2001. Sarma AV, Schottenfeld D, Semin Urol Oncol 2002 20 1 3 9 10.1053/suro.2002.30390 11828352
21. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI, J Urol 2012 188 1 73 83 22578732
22. Individualized estimation of the benefit of radical prostatectomy from the Scandinavian Prostate Cancer Group randomized trial. Vickers A, Bennette C, Steineck G, Adami HO, Johansson JE, Bill-Axelson A, Palmgren J, Garmo H, Holmberg L, Eur Urol 2012 62 2 204 209 10.1016/j.eururo.2012.04.024 22541389
23. Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy in clinically localized prostate cancer. Hennenfent BR, Br J Urol 1998 82 1 166